Human skin has unique properties of which functioning as a physicochemical
barrier is one of the most apparent. The human integument is able to resist
the penetration of many molecules. However, especially smaller molecules c
an surpass transcutaneously. They are able to go by the corneal layer, whic
h is thought to form the main deterrent. We argue that the molecular weight
(MW) of a compound must be under 500 Dalton to allow skin absorption. Larg
er molecules cannot pass the corneal layer. Arguments for this "500 Dalton
rule" are; 1) virtually all common contact allergens are under 500 Dalton,
larger molecules are not known as contact sensitizers. They cannot penetrat
e and thus cannot act as allergens in man; 2) the most commonly used pharma
cological agents applied in topical dermatotherapy are all under 500 Dalton
; 3) all known topical drugs used in transdermal drug-delivery systems are
under 500 Dalton. In addition, clinical experience with topical agents such
as cyclosporine, tacrolimus and ascomycins gives further arguments for the
reality of the 500 Dalton rule. For pharmaceutical development purposes, i
t seems logical to restrict the development of new innovative compounds to
a MW of under 500 Dalton, when topical dermatological therapy or percutaneo
us systemic therapy or vaccination is the objective.